Enfeksiyon Hastalıklarında Son Gelişmeler: CRISPR/CAS9 Uygulamaları

. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014;346(6213): 1258096. doi: 10.1126/science.1258096.

Li H, Yang Y, Hong W, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther, 2020;5(1): 1. doi: 10.1038/s41392-019-0089-y.

Akbudak MA, Kontbay K. Yeni nesil genom düzenleme teknikleri:

ZFN, TALEN, CRISPR’lar ve bitkilerde kullanımı. Tarla Bitkileri Merkez Araştırma Enstitüsü Dergisi, 2017;26 (1): 111-126.

Trevisan M, Palù G, Barzon L. Genome editing technologies to fight infectious diseases. Expert Rev Anti Infect Ther, 2017;15(11): 1001-1013. doi: 10.1080/14787210.2017.1400379.

Luo ML, Leenay RT, Beisel CL. Current and future prospects for CRISPR-based tools in bacteria. Biotechnol Bioeng, 2016;113(5): 930-943. doi: 10.1002/bit.25851.

Greene AC. CRISPR-based antibacterials: transforming bacterial defense into offense. Trends Biotechnol, 2018;36(2): 127-130. doi: 10.1016/j.tibtech.2017.10.021.

Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol, 1987;169(12): 5429-5433. doi: 10.1128/jb.169.12.5429-5433.1987.

Jinek M, Chylinski K, Fonfara I, et al A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 201217;337(6096): 816-821. doi: 10.1126/science.1225829.

Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature, 2012;482(7385): 331-338. doi: 10.1038/nature10886.

Chylinski K, Makarova KS, Charpentier E, et al. Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res, 2014;42(10): 6091-6105. doi: 10.1093/nar/gku241.

Bayat H, Modarressi MH, Rahimpour A. The conspicuity of CRISPR-Cpf1 system as a significant breakthrough in genome editing. Curr Microbiol, 2018;75(1): 107-115. doi: 10.1007/s00284-017-1406-8. 12. Khadempar S, Familghadakchi S, Motlagh RA, et al. CRISPR-Cas9 in genome editing: Its function and medical applications. J Cell Physiol, 2019;234(5): 5751-5761. doi: 10.1002/jcp.27476.

Gebre M, Nomburg JL, Gewurz BE. CRISPR-Cas9 genetic analysis of virus-host interactions. Viruses, 2018;10(2): 55. doi: 10.3390/v10020055.

Saayman S, Ali SA, Morris KV, Weinberg MS. The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther. 2015 Jun;15(6):819-30. doi: 10.1517/14712598.2015.1036736.

Wright AV, Sternberg SH, Taylor DW, et al. Rational design of a split-Cas9 enzyme complex. Proc Natl Acad Sci U S A, 2015;112(10): 2984-2989. doi: 10.1073/pnas.1501698112.

Jiang F, Zhou K, Ma L, et al. Structural biology. A Cas9-guide RNA complex preorganized for target DNA recognition. Science, 2015;348(6242): 1477-1481. doi: 10.1126/science.aab1452.

Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc, 2013;8(11): 2281-2308. doi: 10.1038/nprot.2013.143.

Lin H, Li G, Peng X, et al. The Use of CRISPR/Cas9 as a tool to study human infectious viruses. Front Cell Infect Microbiol, 2021;27;11: 590989. doi: 10.3389/fcimb.2021.590989.

Lino CA, Harper JC, Carney JP, et al. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv, 2018;25(1): 1234-1257. doi: 10.1080/10717544.2018.1474964.

Xie H, Tang L, He X, et al. SaCas9 requires 5'-NNGRRT-3' PAM for sufficient cleavage and possesses higher cleavage activity than SpCas9 or FnCpf1 in human cells. Biotechnol J, 2018;13(4) :e1700561. doi: 10.1002/biot.201700561.

Peters JM, Colavin A, Shi H, et al. A Comprehensive, CRISPR-based functional analysis of essential genes in bacteria. Cell, 2016;165(6): 1493-1506. doi: 10.1016/j.cell.2016.05.003.

Tao L, Zhang J, Meraner P, et al. Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature, 2016;538(7625): 350-355. doi: 10.1038/nature19799.

Rousset F, Cabezas-Caballero J, Piastra-Facon F, et al. The impact of genetic diversity on gene essentiality within the Escherichia coli species. Nat Microbiol, 2021;6(3): 301-312. doi: 10.1038/s41564-020-00839-y.

Peters JM, Koo BM, Patino R, et al. Enabling genetic analysis of diverse bacteria with Mobile-CRISPRi. Nat Microbiol, 2019;4(2): 244-250. doi: 10.1038/s41564-018-0327-z.

Zheng K, Wang Y, Li N, et al. Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion. Commun Biol, 2018;1: 32. doi: 10.1038/s42003-018-0035-5.

Pardee K, Green AA, Takahashi MK, et al. Rapid, low-cost detection of Zika Virus using programmable biomolecular components. Cell, 2016;165(5): 1255-1266. doi: 10.1016/j.cell.2016.04.059.

Müller V, Rajer F, Frykholm K, et al. Direct identification of antibiotic resistance genes on single plasmid molecules using CRISPR/Cas9 in combination with optical DNA mapping. Sci Rep, 2016;6: 37938. doi: 10.1038/srep37938.

Kellner MJ, Koob JG, Gootenberg JS, et al. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc, 2019;14(10): 2986-3012. doi: 10.1038/s41596-019-0210-2.

de la Fuente-Núñez C, Lu TK. CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects. Integr Biol (Camb), 2017;9(2): 109-122. doi: 10.1039/c6ib00140h.

Shukla A, Jani N, Polra M, et al. CRISPR: The multidrug resistance endgame? Mol Biotechnol, 2021;63(8): 676-685. doi: 10.1007/s12033-021-00340-9.

Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother, 2003;51Suppl2: 9-16. doi: 10.1093/jac/dkg249.

Peterson E, Kaur P. Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens. Front Microbiol, 2018;9: 2928. doi: 10.3389/fmicb.2018.02928.

Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: A guide for clinicians. J Anaesthesiol Clin Pharmacol, 2017;33(3): 300-305. doi: 10.4103/joacp.JOACP_349_15.

Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol, 2018;4(3): 482-501. doi: 10.3934/microbiol.2018.3.482.

Gomaa AA, Klumpe HE, Luo ML, et al. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio, 2014;5(1): e00928-13. doi: 10.1128/mBio.00928-13.

Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol, 2014;32(11): 1146-1150. doi: 10.1038/nbt.3043.

Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol, 2014;32(11): 1141-1145. doi: 10.1038/nbt.3011.

Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 2013;152(5): 1173-1183. doi: 10.1016/j.cell.2013.02.022.

Strich JR, Chertow DS. CRISPR-Cas biology and its application to infectious diseases. J Clin Microbiol, 2019;57(4): e01307-18. doi: 10.1128/JCM.01307-18.

Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet, 2015;16(5): 299-311. doi: 10.1038/nrg3899.

Gilbert LA, Horlbeck MA, Adamson B, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell, 2014; 159(3): 647-661. doi: 10.1016/j.cell.2014.09.029.

Rodrigues M, McBride SW, Hullahalli K, et al. Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant Enterococci. Antimicrob Agents Chemother, 2019;63(11): e01454-19. doi: 10.1128/AAC.01454-19.

Krom RJ, Bhargava P, Lobritz MA, et. Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Lett, 2015;15(7): 4808-4813. doi: 10.1021/acs.nanolett.5b01943.

Samson JE, Magadán AH, Sabri M, et al. Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol, 2013;11(10): 675-687. doi: 10.1038/nrmicro3096.

Fage C, Lemire N, Moineau S. Delivery of CRISPR-Cas systems using phage-based vectors. Curr Opin Biotechnol, 2021;68: 174-180. doi: 10.1016/j.copbio.2020.11.012.

Torgerson PR, Devleesschauwer B, Praet N, et al. World Health Organization estimates of the global and regional disease burden of 11 foodborne parasitic diseases, 2010: A data synthesis. PLoS Med, 2015;12(12): e1001920. doi: 10.1371/journal.pmed.1001920.

Hewitson JP, Maizels RM. Vaccination against helminth parasite infections. Expert Rev Vaccines, 2014;13(4): 473-487. doi: 10.1586/14760584.2014.893195.

McVeigh P, Maule AG. Can CRISPR help in the fight against parasitic worms? Elife, 2019;8: e44382. doi: 10.7554/eLife.44382.

Howe KL, Bolt BJ, Shafie M, et al ParaSite - a comprehensive resource for helminth genomics. Mol Biochem Parasitol, 2017;215: 2-10. doi: 10.1016/j.molbiopara.2016.11.005.

Beckmann S, Grevelding CG. Paving the way for transgenic schistosomes. Parasitology, 2012;139(5): 651-668. doi: 10.1017/S0031182011001466.

Dalzell JJ, Warnock ND, McVeigh P, et al. Considering RNAi experimental design in parasitic helminths. Parasitology, 2012;139(5): 589-604. doi: 10.1017/S0031182011001946.

Kirti A, Sharma M, Rani K, et al. CRISPRing protozoan parasites to better understand the biology of diseases. Prog Mol Biol Transl Sci, 2021;180: 21-68. doi: 10.1016/bs.pmbts.2021.01.004.

Serajian S, Ahmadpour E, Oliveira SMR, et al. CRISPR-Cas technology: emerging applications in clinical microbiology and Infectious diseases. Pharmaceuticals, 2021;14(11): 1171. doi: 10.3390/ph14111171.

Bryant JM, Baumgarten S, Glover L, et al. CRISPR in parasitology: not exactly cut and dried! Trends Parasitol, 2019;35(6): 409-422. doi: 10.1016/j.pt.2019.03.004.

Singer M, Marshall J, Heiss K, et al. Zinc finger nuclease-based double-strand breaks attenuate malaria parasites and reveal rare microhomology-mediated end joining. Genome Biol, 2015;16: 249. doi: 10.1186/s13059-015-0811-1.

Ghorbal M, Gorman M, Macpherson CR, et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol, 2014;32(8): 819-821. doi: 10.1038/nbt.2925.

Wagner JC, Platt RJ, Goldfless SJ, et al. Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum. Nat Methods, 2014;11(9): 915-918. doi: 10.1038/nmeth.3063.

Shen B, Brown KM, Lee TD, et al. Efficient gene disruption in diverse strains of Toxoplasma gondii using CRISPR/CAS9. mBio, 2014;5(3): e01114-14. doi: 10.1128/mBio.01114-14.

Sidik SM, Hackett CG, Tran F, et al. Efficient genome engineering of Toxoplasma gondii using CRISPR/Cas9. PLoS One, 2014;9(6): e100450. doi: 10.1371/journal.pone.0100450.

Wang JL, Huang SY, Li TT, et al. Evaluation of the basic functions of six calcium-dependent protein kinases in Toxoplasma gondii using CRISPR-Cas9 system. Parasitol Res, 2016;115(2): 697-702. doi: 10.1007/s00436-015-4791-6.

Striepen B. Parasitic infections: Time to tackle cryptosporidiosis. Nature, 2013;503(7475): 189-191. doi: 10.1038/503189a.

Vinayak S, Pawlowic MC, Sateriale A, et al. Genetic modification of the diarrhoeal pathogen Cryptosporidium parvum. Nature, 2015;523(7561): 477-480. doi: 10.1038/nature14651.

Gang SS, Castelletto ML, Bryant AS, et al. Targeted mutagenesis in a human-parasitic nematode. PLoS Pathog, 2017;13(10): e1006675. doi: 10.1371/journal.ppat.1006675.

Janssen BD, Chen YP, Molgora BM, et al. CRISPR/Cas9-mediated gene modification and gene knock out in the human-infective parasite Trichomonas vaginalis. Sci Rep, 2018;8(1): 270. doi: 10.1038/s41598-017-18442-3.